Format

Send to

Choose Destination
See comment in PubMed Commons below
J Dermatolog Treat. 2015 Jun;26(3):266-8. doi: 10.3109/09546634.2014.946381. Epub 2014 Aug 6.

Racial differences in the use of extracorporeal photopheresis for mycosis fungoides.

Author information

1
Department of Dermatology, Johns Hopkins School of Medicine , Baltimore, MD , USA.

Abstract

BACKGROUND:

Extracorporeal photopheresis (ECP) is an effective treatment option for mycosis fungoides (MF) and associated with few systemic side effects.

OBJECTIVE:

We sought to investigate whether there were differences in rates of ECP use between African-American and Caucasian patients with stage III/IV MF.

METHODS:

We conducted a retrospective review of all patients treated for MF at the Johns Hopkins Hospital main campus outpatient clinic between 1999 and 2011.

RESULTS:

We identified 65 patients with stage III or IV disease, 20 African-American and 45 Caucasian. Only 7 of 20 African-American patients (35%) compared with 30 of 45 (66%) of Caucasian patients were treated with ECP (p = 0.029). In addition, ECP was discussed as an option for 45% of African-Americans compared to 82% of Caucasians (p = 0.007). When discussed as an option, African-Americans and Caucasians had identical rates of ECP use (78% vs 81%, p = 0.841).

CONCLUSIONS:

Differences in rates of ECP use exist among African-American patients when compared to their Caucasian counterparts and may be related to how often ECP is offered as a treatment option. Improving physician awareness of the factors that influence treatment decision making may help diminish discrepancies in treatment regimens among patients with MF.

KEYWORDS:

Cutaneous T-cell lymphoma; ECP; ethnic skin; mycosis fungoides

PMID:
25034002
DOI:
10.3109/09546634.2014.946381
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center